Uttar Pradesh has operationalised various strategies under the NRHM. The State has set up the Institutional Framework of the Mission including the State Health Mission and State and District Health Societies. They have also issued Government orders for setting up the Village Health and Sanitation Committee and Rogi Kalyan Samities. Besides the release of funds for ongoing Disease Control Programmes and other National Programmes, Rs. 180.45 crore was released to Uttar Pradesh for other NRHM initiatives during FY 2005-06. This amount was allocated for selection and training of ASHAs and her Drug Kits, untied funds for sub-centres, upgradation of CHCs to IPHS, additional drug supply to FRUs/CHCS and routine immunization.

Monitoring of clinical trials

*97. DR. VIJAY MALLYA: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether it is a fact that some of the leading pharmaceutical companies have launched programmes for developing new drugs for curing diseases such as cancer, diabetes, arthritis, etc.;

(b) if so, the names of companies together with the products they have developed/are in the process of developing;

(c) whether the statutory clinical trials have been completed, if not, the stage at which these trials are being conducted;

(d) what efforts are being made to avoid side effects on consumption of such drugs and whether the developments are monitored by Government agencies; and

(e) by when these drugs would be ready for use?

THE MINISTER OF HEALTH AND FAMILY WELFARE (DR. ANBUMANI RAMDOSS): (a) to (e) Yes, Sir. A number of Indian Pharmaceutical companies have launched drug discovery/development programmes. Some of the new drugs being developed are indicated for cancer, diabetes, arthritis etc.

Information regarding companies together with products being developed is annexed as per Statement (*See* below).

The molecules currently are at various phases of clinical trials (*i.e.* Phase I/II), which provide a picture about safety and efficacy profile of a new molecule. Permission to conduct Phase I clinical trial is given after critical examination of pre-clinical data (animal toxicity) by a panel of experts. At every stage of clinical trial, prior approval is required. Only after completion of all phases of clinical trials, approval for manufacture and marketing of the drug is granted. To avoid side effects on consumption of such drugs, Post Marketing Surveillance (PMS) studies are further required to be undertaken. Since these new molecules have not yet reached market approval stage, the question of their consumption by patients does not arise.

Statement

List of companies together with products being developed

Sl. No.	Name of Firm	Name of IND	Category	Status
1.	Lupin	LL-4218	Anti-Psoriasis	Phase II Clinical Trial Permission Granted
2.	Ranbaxy	RBx 7644 (Ranbezolid)	Antibiotic	Phase I Clinical Trial Permission Granted
3.	Lupin	LLL-3348 (Desoris)	Anti-Psoriasis	Phase II Clinical Trial Permission Granted
4.	Sun	133H	H1 Receptor Antihistamine	Phase I Clinical Trial Permission Granted
5.	Dr. Reddy Labs	DRF 1644 HCl	Anticancer (Camtothecin)	Phase I Clinical Trial Permission Granted
6.	Lupin	LL-4858	Anti-Tubercular (Sudoterb)	Phase I Clinical Trial Permission Granted
7.	Wockhardt	WCK-1152	Antibacterial	Phase I Clinical Trial Permission Granted
8.	Ranbaxy	RBx 7796 Clafrinast (Earlier RBx4638)	Anti-Asthmatic	Phase II Clinical Trial Permission Granted
9.	Ranbaxy	RBx 11160	Antimalarial	Phase II Clinical Trial Permission Granted
10.	Dr. Reddy Labs	DRF 10945		Anti-Dyslipidemic Phase I Clinical Trial Permission Granted

Sl. No.	Name of Firm	Name of IND	Category	Status
11.	Zydus Cadila	ZYH1	For treatment of Hyperlipidemia	Phase I Clinical Trial Permission Granted
12.	Ranbaxy	RBx 2258 (Parvosin)	Alpha 1 Adrenoreceptor BPH	Phase II Clinical Trial Permission Granted
13.	Ranbaxy	RBx 10558	HMG CoA Reductase Inhibitor having antilipoproteinimic activity	Phase I Clinical Trial Permission Granted
14.	Malladi Drugs	Thrombinase	For Blood Clot Disorders	Phase I Clinical Trial Permission Granted
15.	CDRI		CT-1 Agent	Anti-Hyperglycemic Phase I Clinical Trial Permission Granted
16.	Dr. Reddy's	2-Deoxy-D-Glucose	In Cerebral Gliomas	Phase III Clinical Trial Permission Granted
17.	Dr. Reddy Labs	DRF 1042	Anticancer	Phase I Clinical Trial Permission Granted
18.	Ranbaxy	RBx 9841	For treatment of Overactive bladder & Urinary incontinence	Phase I Clinical Trial Permission Granted
19.	Wockhardt	WCK 771	Antibacterial	Phase II Clinical Trial Permission Granted
20.	CDRI	CDR 134D-123	Antihyperglycemic	Phase I Clinical Trial Permission Granted
21.	Dabur	DRF 7295	Anticancer	Phase II Clinical Trial Permission Granted
22.	CDRI	80/574	Hypolipidemic Agent	Phase III Clinical Trial Permission Granted
23.	Nicholas Piramal	P276-00	Anticancer Agent	Phase I Clinical Trial Permission Granted
24.	Zydus Cadila	ZYI 1	Antiinflammatory	Phase II Clinical Trial Permission Granted
25.	Zydus Cadila	ZYH2	Anti-Dyslipidemic Agent	Phase I Clinical Trial Permission Granted